Abstract library

12 results for "SOM230".
#447 SOMscan: Towards a Ga-68-labeled Pan-Somatostatin PET Imaging Probe Based on SOM230 (Pasireotide)
Introduction: The somatostatin receptor subtype sst2 is largely expressed on neuroendocrine tumors. However, current clinical studies indicate that the subtypes sst1, 3, 5 are of substantial relevance as well.
Conference: 9th Annual ENETS Conference (2012)
Category: Basic
Presenting Author: Dr. Melpomeni Fani
Authors: Fani M, Braun F, Mann A, Kiewer A, ...
Keywords: SOM230, Ga-68, PET imaging
#19 Antitumor activity of Pasireotide (SOM230) alone and in combination with Everolimus (RAD001) in DU-145 human prostate cancer model
Introduction: Pasireotide (SOM230) is a novel multi-receptor ligand somatostatin analogue with high affinity for somatostatin receptor subtypes sst1,2,3 and sst5. Like octreotide, which binds primarily to sst2, it inhibits hypersecretion of hormones from patients with functional pituitary tumors and gastroenteropancreatic neuroendocrine (GEP/NET) tumors. In addition, tumor shrinkage has been observed with both compounds in patients with acromegaly, Cushing’s disease and GEP/NETs, but its tumor-reducing mechanism of action has so far not been revealed. In patients with breast and liver cancer, octreotide had little or no antitumor activity.
Conference: 7th Annual ENETS Conference (2010)
Category: Basic
Presenting Author: Dr. Herbert A. Schmid
Authors: Schmid H A, Chiara L, Nuciforo P, ...
#131 Efficacy and safety results from a Phase II study of pasireotide (SOM230) in the treatment of patients with metastatic NETs refractory or resistant to octreotide LAR
Introduction: Pasireotide, a multi-receptor targeted somatostatin analogue, has 30-, 5- and 39-fold greater affinity for sst1,3 and sst5 receptors, respectively, and a slightly lower affinity for sst2, than octreotide. Because of this multi-receptor binding profile, pasireotide may be effective in controlling symptoms of carcinoid syndrome in patients with gastroenteropancreatic neuroendocrine tumors (NETs) who are no longer responsive to currently available somatostatin analogues.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Dr Larry K Kvols
#266 Everolimus Reduces Cell Viability in Selected Human Medullary Thyroid Carcinoma Primary Cultures
Introduction: It has been demonstrated that everolimus, an mTOR inhibitor, has a potent anti-proliferative effect in a human Medullary Thyroid Carcinoma (MTC) cell line, TT, and in two human MTC primary cultures.
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: MD Maria Chiara Zatelli
#747 A Single-Center, Open-Label, Phase II, Proof-of-Concept Study with Pasireotide LAR in Patients with Progressive Medullary Thyroid Cancer (MTC): Preliminary Data
Introduction: MTC is a well-differentiated neuroendocrine tumor in which somatostatin receptor (sst) expression is higher for sst1 and sst5 than for sst2. This may explain why the available sst2–selective analogues do not work in these patients and why pasireotide (SOM230), a novel, multi-receptor targeted somatostatin analogue with high-binding affinity for sst1, 2, 3 and sst5 could be effective.
Conference: 10th Annual ENETS Conference (2013)
Category: Basic Science - mTOR and other pathways, signalling, receptors
Presenting Author: Valeria Ramundo
#450 Peptide Receptor Radionuclide Therapy for Neuroendocrine Tumors in Germany: First Results of a Multiinstitutional Cancer Registry
Introduction: Peptide receptor radionuclide therapy is an effective treatment option for patients with well-differentiated somatostatin receptor expressing neuroendocrine tumors. However, published data results mainly from retrospective monocentric studies.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Prof. Dr. Dieter Hörsch
#1161 Comparative Proteomic Analysis of Human Insulinoma and Its Clinical Implications in Pancreatic Neuroendocrine Tumors
Introduction: Insulinoma is the most common functional PNET. Its molecular tumorigenesis is largely unknown and proteomic study on insulinoma has not been reported
Conference: 12th Annual ENETS Conference (2015)
Category: Basic Science - Genetics, epigenetics, miRNAs
Presenting Author: Dr Yuan-Jia Chen
Authors: Qiao X W, Song Y L, Bai C M, Zhu L M, ...
#1255 NETs in Russian Cancer Center Hospital Registry
Introduction: Studies show an increasing number of pts diagnosed with NETs within the study period 1990 - 2015.
Conference: 13th Annual ENETS conference (2016)
Category: Epidemiology/Natural history/Prognosis - Registries, nationwide and regional surveys
Presenting Author: Alexander Kuzminov
#1286 A Comparative Analysis of Ki67 Index of the High Grade Neuroendocrine Neoplasms Arising in the Gastrointestinal Tract and the Pancreas
Introduction: A common classification has been used for NET in gastrointestinal tract (GI-NET) and pancreas (P-NET), but heterogeneity has been reported in high grade tumors; well-differentiated G3 (WDG3), poorly differentiated NEC (NEC), and mixed adenoneuroendocrine carcinoma (MANEC).
Conference: 13th Annual ENETS conference (2016)
Category: Pathology, grading, staging
Presenting Author: Atsuko Kasajima
#1508 NETTER-1 Phase III in Patients with Midgut Neuroendocrine Tumors Treated with 177Lu-Dotatate: Efficacy and Safety Results
Introduction: There are limited therapeutic options for patients with advanced midgut NETs progressing on first-line somatostatin analog therapy.
Conference: 13th Annual ENETS conference (2016)
Category: PRRT-Ablative therapies-Endoscopic treatment
Presenting Author: MD Jonathan Strosberg
Authors: Strosberg J, Wolin E, Chasen B, Kulke M, ...
Keywords: Lutathera, PRRT, NET